Kelch-like Protein 3 in Human Disease and Therapy

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 May 18

PMID 35585379

Authors

Yan Lin

Qian Li

Xiaofeng Jin

Affiliations

Soon will be listed here.

Abstract

Kelch-like protein 3 (KLHL3) is a substrate adaptor of Cullin3-RING ubiquitin ligase (CRL3), and KLHL3-CUL3 complex plays a vital role in the ubiquitination of specific substrates. Mutations and abnormal post-translational modifications of KLHL3-CUL3 affect substrate ubiquitination and may related to the pathogenesis of Gordon syndrome (GS), Primary Hyperparathyroidism (PHPT), Diabetes Mellitus (DM), Congenital Heart Disease (CHD), Pre-eclampsia (PE) and even cancers. Therefore, it is essential to understand the function and molecular mechanisms of KLHL3-CUL3 for the treatment of related diseases. In this review, we summary the structure and function of KLHL3-CUL3, the effect of KLHL3-CUL3 mutations and aberrant modifications in GS, PHPT, DM, CHD and PE. Moreover, we noted a possible role of KLHL3-CUL3 in carcinogenesis and provided ideas for targeting KLHL3-CUL3 for related disease treatment.

Citing Articles

Changes in DNA Methylation and mRNA Expression in Lung Tissue after Long-Term Supplementation with an Increased Dose of Cholecalciferol.

Wierzbicka A, Semik-Gurgul E, Swiatkiewicz M, Szmatola T, Steg A, Oczkowicz M Int J Mol Sci. 2024; 25(1).

PMID: 38203636 PMC: 10778667. DOI: 10.3390/ijms25010464.

Gordon's syndrome in pregnancy.

Morton A Obstet Med. 2023; 16(3):151-155.

PMID: 37720005 PMC: 10504880. DOI: 10.1177/1753495X221146331.

References

Wang R, Wang G . Protein Modification and Autophagy Activation. Adv Exp Med Biol. 2019; 1206:237-259. DOI: 10.1007/978-981-15-0602-4_12. View

Rape M . Ubiquitylation at the crossroads of development and disease. Nat Rev Mol Cell Biol. 2017; 19(1):59-70. DOI: 10.1038/nrm.2017.83. View

Duffy M, Synnott N, OGrady S, Crown J . Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020; 79:58-67. DOI: 10.1016/j.semcancer.2020.07.005. View

Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B . MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020; 34(11):2858-2874. DOI: 10.1038/s41375-020-0949-z. View

Wang P, Song J, Ye D . CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases. Adv Exp Med Biol. 2020; 1217:211-223. DOI: 10.1007/978-981-15-1025-0_13. View

Dhanoa B, Cogliati T, Satish A, Bruford E, Friedman J . Update on the Kelch-like (KLHL) gene family. Hum Genomics. 2013; 7:13. PMC: 3658946. DOI: 10.1186/1479-7364-7-13. View

Mitsuishi Y, Motohashi H, Yamamoto M . The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol. 2012; 2:200. PMC: 3530133. DOI: 10.3389/fonc.2012.00200. View

Takahashi D, Mori T, Wakabayashi M, Mori Y, Susa K, Zeniya M . KLHL2 interacts with and ubiquitinates WNK kinases. Biochem Biophys Res Commun. 2013; 437(3):457-62. DOI: 10.1016/j.bbrc.2013.06.104. View

Ishizawa K, Wang Q, Li J, Yamazaki O, Tamura Y, Fujigaki Y . Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling. Proc Natl Acad Sci U S A. 2019; 116(8):3155-3160. PMC: 6386661. DOI: 10.1073/pnas.1817281116. View

10.

Xiang S, Shi X, Chen P, Chen Y, Bing S, Jin X . Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy. Pharmacol Res. 2021; 169:105616. DOI: 10.1016/j.phrs.2021.105616. View

11.

Boyden L, Choi M, Choate K, Nelson-Williams C, Farhi A, Toka H . Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012; 482(7383):98-102. PMC: 3278668. DOI: 10.1038/nature10814. View

12.

Wang L, Jiang C, Cai R, Chen X, Peng J . Unveiling the Distinct Mechanisms by which Disease-Causing Mutations in the Kelch Domain of KLHL3 Disrupt the Interaction with the Acidic Motif of WNK4 through Molecular Dynamics Simulation. Biochemistry. 2019; 58(16):2105-2115. PMC: 6688613. DOI: 10.1021/acs.biochem.9b00066. View

13.

Wimuttisuk W, Singer J . The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer. Mol Biol Cell. 2006; 18(3):899-909. PMC: 1805106. DOI: 10.1091/mbc.e06-06-0542. View

14.

Schumacher F, Siew K, Zhang J, Johnson C, Wood N, Cleary S . Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia. EMBO Mol Med. 2015; 7(10):1285-306. PMC: 4604684. DOI: 10.15252/emmm.201505444. View

15.

Zhang Y, Jiang G, Zhang C . Downregulation of Cullin 3 Ligase Signaling Pathways Contributes to Hypertension in Preeclampsia. Front Cardiovasc Med. 2021; 8:654254. PMC: 8076533. DOI: 10.3389/fcvm.2021.654254. View

16.

Cornelius R, Yang C, Ellison D . Hypertension-causing cullin 3 mutations disrupt COP9 signalosome binding. Am J Physiol Renal Physiol. 2019; 318(1):F204-F208. PMC: 6985821. DOI: 10.1152/ajprenal.00497.2019. View

17.

Lingaraju G, Bunker R, Cavadini S, Hess D, Hassiepen U, Renatus M . Crystal structure of the human COP9 signalosome. Nature. 2014; 512(7513):161-5. DOI: 10.1038/nature13566. View

18.

Ohta A, Schumacher F, Mehellou Y, Johnson C, Knebel A, Macartney T . The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochem J. 2013; 451(1):111-22. PMC: 3632089. DOI: 10.1042/BJ20121903. View

19.

Shi X, Xiang S, Cao J, Zhu H, Yang B, He Q . Kelch-like proteins: Physiological functions and relationships with diseases. Pharmacol Res. 2019; 148:104404. DOI: 10.1016/j.phrs.2019.104404. View

20.

Yoshizaki Y, Mori Y, Tsuzaki Y, Mori T, Nomura N, Wakabayashi M . Impaired degradation of WNK by Akt and PKA phosphorylation of KLHL3. Biochem Biophys Res Commun. 2015; 467(2):229-34. DOI: 10.1016/j.bbrc.2015.09.184. View